See more : Lepidico Limited (LPD.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Dalian BIO-CHEM Company Limited (603360.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dalian BIO-CHEM Company Limited, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- ECARX Holdings Inc. (ECXWW) Income Statement Analysis – Financial Results
- Aligos Therapeutics, Inc. (ALGS) Income Statement Analysis – Financial Results
- Carnival Corporation & plc (CUKPF) Income Statement Analysis – Financial Results
- SolidWorld Group S.p.A. (S3D.MI) Income Statement Analysis – Financial Results
- Adamant Holdings Inc. (UCCPF) Income Statement Analysis – Financial Results
Dalian BIO-CHEM Company Limited (603360.SS)
About Dalian BIO-CHEM Company Limited
Dalian BIO-CHEM Company Limited produces and sells bactericides, antiseptics, and fungicides for various industrial applications in Europe, North and South Americas, the Middle East, Africa, and Asia. The company's products are used as disinfection; algaecide in water treatment, such as petrochemicals, electricity, central air conditioning, and industrial cooling water; anti-corrosion in emulsions, mineral slurries, pigment dispersions, adhesives, tackifiers, metalworking fluids, and cosmetics aqueous system; and aqueous system of leather, paint and coating, textile, and dyeing. Its products also used for anti-mildew and anti-algae applications, as well as manufactures dry film preservative, which is used for paints and coatings. Dalian BIO-CHEM Company Limited was founded in 2003 and is based in Dalian, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.07B | 1.26B | 1.01B | 749.54M | 871.90M | 528.17M | 410.36M | 389.43M | 327.99M | 346.64M | 291.38M | 256.55M | 208.55M |
| Cost of Revenue | 520.77M | 588.58M | 536.47M | 335.80M | 340.76M | 273.24M | 200.11M | 193.93M | 181.27M | 202.74M | 164.16M | 149.40M | 122.03M |
| Gross Profit | 544.89M | 668.08M | 469.79M | 413.74M | 531.14M | 254.93M | 210.25M | 195.51M | 146.72M | 143.90M | 127.22M | 107.15M | 86.53M |
| Gross Profit Ratio | 51.13% | 53.16% | 46.69% | 55.20% | 60.92% | 48.27% | 51.24% | 50.20% | 44.73% | 41.51% | 43.66% | 41.77% | 41.49% |
| Research & Development | 38.98M | 47.14M | 40.03M | 28.57M | 28.14M | 19.15M | 15.17M | 13.99M | 10.38M | 4.82M | 4.11M | 7.28M | 0.00 |
| General & Administrative | 106.62M | 51.35M | 60.52M | 49.75M | 67.95M | 11.14M | 10.65M | 8.76M | 9.40M | 8.54M | 10.47M | 29.79M | 21.87M |
| Selling & Marketing | 13.90M | 11.46M | 12.07M | 10.38M | 35.02M | 26.09M | 21.33M | 19.55M | 17.54M | 19.69M | 18.75M | 16.49M | 10.82M |
| SG&A | 119.10M | 62.81M | 72.59M | 60.12M | 102.97M | 37.23M | 31.99M | 28.31M | 26.94M | 28.23M | 29.22M | 46.28M | 32.69M |
| Other Expenses | 0.00 | 93.72M | 40.72M | 54.02M | 34.04M | -497.46K | -78.07K | 6.77M | 4.53M | 6.32M | 4.01M | 4.30M | 3.33M |
| Operating Expenses | 168.50M | 203.67M | 153.34M | 142.71M | 165.15M | 90.72M | 77.51M | 80.76M | 73.81M | 64.34M | 60.83M | 48.71M | 33.83M |
| Cost & Expenses | 679.74M | 792.25M | 689.81M | 478.51M | 505.90M | 363.97M | 277.62M | 274.69M | 255.08M | 267.08M | 224.99M | 198.11M | 155.86M |
| Interest Income | 18.79M | 3.55M | 3.75M | 11.00M | 1.94M | 1.52M | 1.04M | 246.34K | 192.99K | 210.54K | 220.57K | 10.07M | -0.42 |
| Interest Expense | 5.32M | 3.72M | 11.77M | 7.68M | 2.36M | 1.07M | 1.09M | 6.44M | 11.81M | 12.29M | 10.91M | 0.00 | 5.38M |
| Depreciation & Amortization | 64.04M | 71.41M | 48.93M | 43.20M | 34.75M | 24.14M | 24.81M | 24.29M | 22.04M | 22.02M | 21.73M | 12.25M | 7.59M |
| EBITDA | 455.06M | 537.38M | 356.25M | 311.37M | 404.76M | 197.08M | 152.48M | 145.89M | 91.88M | 100.43M | 89.15M | 58.44M | 53.80M |
| EBITDA Ratio | 42.70% | 43.56% | 35.40% | 42.62% | 46.84% | 37.09% | 38.35% | 38.64% | 31.44% | 31.30% | 30.90% | 23.06% | 25.80% |
| Operating Income | 385.92M | 461.63M | 302.72M | 260.72M | 367.54M | 172.12M | 126.46M | 108.34M | 61.65M | 66.71M | 52.50M | 46.91M | 46.21M |
| Operating Income Ratio | 36.21% | 36.73% | 30.08% | 34.78% | 42.15% | 32.59% | 30.82% | 27.82% | 18.80% | 19.24% | 18.02% | 18.28% | 22.16% |
| Total Other Income/Expenses | -143.78K | -196.19K | -10.68M | -447.66K | -120.19K | 13.42M | -78.07K | 6.68M | 4.53M | -5.41M | -9.00M | -7.95M | 3.33M |
| Income Before Tax | 385.78M | 461.43M | 292.04M | 260.27M | 367.42M | 171.62M | 126.38M | 115.02M | 66.19M | 72.99M | 56.51M | 51.21M | 49.54M |
| Income Before Tax Ratio | 36.20% | 36.72% | 29.02% | 34.72% | 42.14% | 32.49% | 30.80% | 29.53% | 20.18% | 21.06% | 19.39% | 19.96% | 23.75% |
| Income Tax Expense | 57.40M | 58.87M | 41.55M | 38.51M | 60.62M | 26.56M | 26.50M | 17.07M | 9.49M | 8.96M | 7.59M | 6.40M | 7.63M |
| Net Income | 328.38M | 402.57M | 250.49M | 221.75M | 306.80M | 145.19M | 100.27M | 98.27M | 57.34M | 64.03M | 48.92M | 44.81M | 41.91M |
| Net Income Ratio | 30.81% | 32.03% | 24.89% | 29.59% | 35.19% | 27.49% | 24.43% | 25.23% | 17.48% | 18.47% | 16.79% | 17.47% | 20.09% |
| EPS | 0.66 | 1.20 | 0.71 | 0.61 | 0.84 | 0.40 | 0.29 | 0.36 | 0.21 | 0.23 | 0.18 | 0.16 | 0.17 |
| EPS Diluted | 0.66 | 1.20 | 0.71 | 0.61 | 0.84 | 0.40 | 0.29 | 0.36 | 0.21 | 0.23 | 0.18 | 0.16 | 0.17 |
| Weighted Avg Shares Out | 494.33M | 334.78M | 350.69M | 365.24M | 365.88M | 364.79M | 350.93M | 275.17M | 276.03M | 274.54M | 273.91M | 273.24M | 249.98M |
| Weighted Avg Shares Out (Dil) | 494.33M | 334.78M | 354.23M | 365.24M | 365.88M | 364.83M | 350.93M | 275.17M | 276.03M | 274.54M | 273.95M | 273.25M | 249.98M |
Source: https://incomestatements.info
Category: Stock Reports